172 related articles for article (PubMed ID: 4634903)
1. [Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects].
Geissbuhler F; Eisenring JJ; Friedli P; Bartholini G; Tissot R
Encephale; 1972; 61(2):127-48. PubMed ID: 4634903
[No Abstract] [Full Text] [Related]
2. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
[No Abstract] [Full Text] [Related]
3. L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients.
Goodwin FK; Murphy DL; Brodie HK; Bunney WE
Biol Psychiatry; 1970 Oct; 2(4):341-66. PubMed ID: 4920729
[No Abstract] [Full Text] [Related]
4. [Cerebral and peripheral consumption of L-5-HTP in patients with manic, depressive or psychotic syndromes].
Gaillard JM; Eisenring JJ; Tissot R
Encephale; 1973; 62(5):395-407. PubMed ID: 4546593
[No Abstract] [Full Text] [Related]
5. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
Guillard A
Brux Med; 1972 Oct; 52(10):673-80. PubMed ID: 4656191
[No Abstract] [Full Text] [Related]
6. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R
Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694
[No Abstract] [Full Text] [Related]
7. [Familial syndrome with parkinsonian tremor and anosmia and its therapy with L-dopa associated with a decarboxylase inhibitor].
Constantinidis J; de Ajuriaguerra J
Therapeutique; 1970 Mar; 46(3):263-9. PubMed ID: 5422192
[No Abstract] [Full Text] [Related]
8. Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
Messiha FS; Hsu TH; Bianchine JR
J Clin Invest; 1972 Feb; 51(2):452-5. PubMed ID: 5009125
[TBL] [Abstract][Full Text] [Related]
9. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
Ferel D
Schweiz Med Wochenschr; 1972 Jan; 102(3):88-94. PubMed ID: 4551909
[No Abstract] [Full Text] [Related]
10. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
Görlich J; Markus E
Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316
[No Abstract] [Full Text] [Related]
11. [Therapy of parkinsonism using a combination of L-dopa and decarboxylase inhibitor].
Völler GW; Muschard F
Med Welt; 1973 Apr; 24(17):705-7. PubMed ID: 4750934
[No Abstract] [Full Text] [Related]
12. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
Stammler A; Vielhaber K
Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
[No Abstract] [Full Text] [Related]
13. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
Andrews CJ; Somerville B
Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
[No Abstract] [Full Text] [Related]
14. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
Kaufmann W; Butz P; Wiesendanger M
Dtsch Z Nervenheilkd; 1970; 197(1):85-100. PubMed ID: 5522871
[No Abstract] [Full Text] [Related]
15. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
De Divitiis E; Cerillo A; Tata MR; Decina A
Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
[No Abstract] [Full Text] [Related]
16. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
Court J; Kase JC; Mena I; Palacios E
Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
[No Abstract] [Full Text] [Related]
17. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
[No Abstract] [Full Text] [Related]
18. [Modalities of treatment of Parkinsonian syndrome with L-dopa].
Yanniotis G; Eisenring JJ; Gauthier G; Tissot R; de Ajuriaguerra J
Int J Neurol; 1972; 9(1):23-32. PubMed ID: 5086635
[No Abstract] [Full Text] [Related]
19. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
[No Abstract] [Full Text] [Related]
20. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
Gattringer B; Steinhäusl H
Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
[No Abstract] [Full Text] [Related]
[Next] [New Search]
